ANDOVER,
Mass., Aug. 2, 2023 /PRNewswire/ -- TransMedics
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology
company that is transforming organ transplant therapy for patients
with end-stage lung, heart, and liver failure, announced today
that is has acquired from Bridge to Life Ltd. ("Bridge to Life"),
assets and intellectual property related to the Ex-Vivo Organ
Support System ("EVOSS") and LifeCradle Heart Preservation
Transport System ("LifeCradle") technologies. EVOSS is a warm
perfusion technology designed for lung and heart transplantation
and LifeCradle is a cold perfusion technology designed for heart
transplantation. TransMedics intends to further develop these
technologies as the company seeks to expand its product offerings
and indications for organ transplantation.
"We are excited for the opportunity to further develop these
innovative technologies and incorporate them into
our Next-Generation OCS technology platform," said
Waleed Hassanein, MD, President and
Chief Executive Officer. "This acquisition positions us to
capitalize on significant strategic opportunities to expand our
product offering, add new clinical indications, further enhance the
National OCS Program (NOP) offering, and maintain our global
leadership position in the organ transplant field."
Canaccord Genuity LLC acted as financial advisor to TransMedics.
Piper Sandler & Co. acted as
financial advisor to Bridge to Life. Ropes & Gray LLP acted as
legal advisor to TransMedics. Cooley LLP acted as legal advisor to
Bridge to Life.
About TransMedics Group, Inc.
TransMedics
is the world's leader in portable extracorporeal warm perfusion and
assessment of donor organs for transplantation. Headquartered in
Andover, Massachusetts, the
company was founded to address the unmet need for more and better
organs for transplantation and has developed technologies to
preserve organ quality, assess organ viability prior to transplant,
and potentially increase the utilization of donor organs for the
treatment of end-stage heart, lung, and liver failure.
Forward-Looking Statements
This press release contains
forward-looking statements with respect to, among other things,
TransMedics' plans for the development of the EVOSS and LifeCradle
technologies; the expansion of TransMedics' product offering and
addition of new clinical indications; TransMedics' ability to
further enhance its National OCS Program offering. These
forward-looking statements are subject to a number of risks and
uncertainties. Our management cannot predict all risks, nor can we
assess the impact of all factors on the extent to which any factor,
or combination of factors, may cause actual results to differ
materially from those contained in or implied by any
forward-looking statements we may make. In light of these risks and
uncertainties, the forward-looking events and circumstances
discussed in this press release may not occur and actual results
could differ materially and adversely from those anticipated in or
implied by the forward-looking statements. Factors that could cause
actual results to differ materially include: risks and
uncertainties related to the development of the EVOSS and
LifeCradle technologies, including the ability to integrate the
technologies into the next generation OCS; the risk
that we may not be able to realize the expected benefits
of the acquisition of the EVOSS or LifeCradle technologies; risks
related to the ability to further grow and enhance the National OCS
Program; and other factors described in our filings with
the Securities and Exchange Commission (the "SEC"),
including under the heading "Risk Factors" in our Annual Report on
Form 10-K for the year ended December 31, 2022, filed with
the SEC on February 27, 2023, Quarterly Report on
Form 10-Q for the period ended March 31,
2023 filed with the SEC on May 4,
2023, and comparable disclosure in our subsequent filings
with the SEC. We will make information available in our annual
and quarterly reports and other filings with the SEC. The
forward-looking statements in this press release speak only as of
the date of this press release. Factors or events that could cause
our actual results to differ may emerge from time to time, and we
are not able to predict all of them. We undertake no obligation to
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by applicable law.
Investor Contact:
Brian
Johnston
332-895-3222
Investors@transmedics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/transmedics-acquires-warm-perfusion-evoss-and-cold-perfusion-lifecradle-technologies-from-bridge-to-life-301892032.html
SOURCE TransMedics Group, Inc.